Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment

BACKGROUND Friedreich ataxia is a neurological disease originating from an iron-sulfur cluster enzyme deficiency due to impaired iron handling in the mitochondrion, aconitase being particularly affected. As a mean to counteract disease progression, it has been suggested to chelate free mitochondrial iron. Recent years have witnessed a renewed interest in this strategy because of availability of...

Dysarthria in Friedreichs Ataxia: A Perceptual Analysis

The aims of this study were to: (1) evaluate the perceptual speech dimensions, speech intelligibility and dys arthria severity of a group of individuals diagnosed with Friedreich’s ataxia (FRDA); (2) determine the presence of subgroups within FRDA dysarthria; (3) investigate the relationship between the speech outcome and the clinical factors of disease progression. The study included 38 indivi...

micrornas: promising potential targets for cancer treatment

P 108: Evaluation of Calcineurin Role in Neuroinflmmation: Possible Targets for Early Detection and Treatment

Calcineurin (CaN) is a Ca2+/calmodulin (Ca2+/CaM)-dependent serine/threonine protein phosphatase expressed in most mammalian tissues but found at higher concentration in brain. In the last decade there have been a steadily increasing number of studies identifying neuronal CaN as a primary suspect in neuronal vulnerability, synapse loss, dendritic atrophy, synaptic dysfunction and neuroinflammat...

P 107: P2x7 Receptors: as a Novel Targets for the Treatment of Neuroinflammation

P2x7 receptors are Purineric receptors that are extracellular ATP-gated ion channel. These receptors require high dose or prolonged exposure to ATP for initial activation. The Activation of these receptors facilitates the formation of inflammasome which activates caspase 1. The P20 and P10 subunits of caspase 1 form active enzyme that then releases active interleukin (IL)-1 β and IL-18, tu...